2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeSpecial Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia
Chwastiak L, Rosenheck R, McEvoy J, Keefe R, Swartz M, Lieberman J. Special Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatric Services 2006, 57: 1102-1109. PMID: 16870960, DOI: 10.1176/ps.2006.57.8.1102.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedComorbidityCross-Sectional StudiesHumansMaleMiddle AgedSchizophreniaSchizophrenic PsychologySeverity of Illness IndexUnited StatesConceptsMedical comorbiditiesMedical conditionsPsychiatric symptom severityPsychosocial functioningNeurocognitive impairmentSchizophrenia symptomsBaseline dataSymptom severityCross-sectional studyPhysical health statusSample of patientsClinical Antipsychotic TrialsPoorer neurocognitive functioningGreater depressive symptomsSevere schizophrenia symptomsSample of personsDiabetes mellitusAntipsychotic pharmacotherapyIndependent associationAntipsychotic TrialsMultivariate regression modelComorbiditiesPsychotic symptomsDepressive symptomsHealth status
2001
Impact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK M, ROSENHECK R, DESAI R, STOLAR M, RIPPER G. Impact of Clozapine Prescription on Inpatient Resource Utilization. The Journal Of Nervous And Mental Disease 2001, 189: 766-773. PMID: 11758660, DOI: 10.1097/00005053-200111000-00006.Peer-Reviewed Original ResearchConceptsInpatient resource utilizationClozapine treatmentInpatient daysComparison groupService utilization variablesMore inpatient daysClozapine prescriptionIndex dischargeRefractory schizophreniaConventional neurolepticsTypical neurolepticsClinical variablesVA databasesInpatient hospitalizationInpatient careYear treatmentUtilization variablesClozapineTreatmentNeurolepticsPatientsSchizophreniaDetecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D, Schizophrenia D. Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia. Schizophrenia Bulletin 2001, 27: 227-234. PMID: 11354590, DOI: 10.1093/oxfordjournals.schbul.a006869.Peer-Reviewed Original Research
1999
Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology
Cicchetti D, Rosenheck R, Showalter D, Charney D, Cramer J. Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology. The Clinical Neuropsychologist 1999, 13: 157-170. PMID: 10949157, DOI: 10.1076/clin.13.2.157.1965.Peer-Reviewed Original ResearchImpact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D, Schizophrenia T. Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal Of Psychiatry 1999, 156: 88-93. PMID: 9892302, DOI: 10.1176/ajp.156.1.88.Peer-Reviewed Original ResearchConceptsRefractory schizophreniaDeficit syndromeNegative symptomsPositive symptomsClozapine's effectVeterans Administration TrialEffects of clozapineImpact of clozapineNegative clinical symptomsProminent negative symptomsClozapine treatmentHospitalized patientsConventional medicationsClinical symptomsControl subjectsAdministration trialClinical subtypesAnalysis of covariancePatientsClozapineSyndromeSymptomsNegative syndromeSchizophreniaTime points
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis
1995
Multisite Experimental Cost Study of Intensive Psychiatric Community Care
Rosenheck R, Neale M, Leaf P, Milstein R, Frisman L. Multisite Experimental Cost Study of Intensive Psychiatric Community Care. Schizophrenia Bulletin 1995, 21: 129-140. PMID: 7770734, DOI: 10.1093/schbul/21.1.129.Peer-Reviewed Original ResearchConceptsControl patientsHealth care service usageIntensive psychiatric community careVeterans Affairs Medical CenterHigh hospital usersPsychiatric community careStandard VA careInpatient service useCommunity care programProgram entryInpatient usageVA careAge 45Medical CenterSurgical hospitalsService usePatientsCare programCommunity careVA costsSociodemographic characteristicsService usageCareComputerized dataCost studies
1993
Who Should Receive High-cost Mental Health Treatment and for How Long?
Rosenheck R, Massari L, Frisman L. Who Should Receive High-cost Mental Health Treatment and for How Long? Schizophrenia Bulletin 1993, 19: 843-852. PMID: 8303231, DOI: 10.1093/schbul/19.4.843.Peer-Reviewed Original ResearchConceptsMental health treatmentInpatient costsCost offsetsHealth treatmentLarger mental health systemVeterans Affairs Medical CenterInpatient service useAverage inpatient costCost-effectiveness studiesFrequent hospital usersCost of treatmentMental health systemHigh-cost interventionsHigh treatment costsHigh-cost treatmentsClinical effectivenessInpatient treatmentMedical CenterHospital useService useSchizophrenia patientsPatientsInpatient expensesExpensive treatmentHealth system